Tumor cell membrane and intracellular proteins

Tumor cell membrane and intracellular proteins is a broad, collective term referring to the entire complement of proteins expressed by cancer cells, including those embedded in the plasma membrane and those located within the cytoplasm or nucleus. This category encompasses a diverse range of molecular classes, such as receptor tyrosine kinases, metabolic enzymes, and transcription factors, many of which are dysregulated to support tumor growth and survival (Source: National Cancer Institute). These proteins are central to the biological hallmarks of cancer, including sustained proliferation, resistance to cell death, and metabolic reprogramming (Source: Hanahan, D., Cell, 2022). Because this term represents a vast and heterogeneous group of molecules rather than a single entity, it is not considered a specific therapeutic target in the traditional sense. Instead, it serves as a conceptual framework for identifying various molecular vulnerabilities that can be exploited by targeted therapies, such as monoclonal antibodies and small-molecule inhibitors (Source: Nature Reviews Cancer, 2021). In some contexts, such as photodynamic therapy or the use of non-specific cytotoxic agents, drugs are described as interacting with these proteins generally due to their preferential accumulation in malignant tissues (Source: FDA Label for Photofrin). Consequently, while biologically significant, this designation lacks the molecular specificity required for a single canonical target entry.

Other names

Tumor-associated proteinsCancer cell proteinsNeoplastic cell proteomeTumor antigens

The mechanisms of action for drugs targeting these proteins are highly variable and depend on the specific protein involved. Common mechanisms include the inhibition of cell surface receptors to block growth signaling, the disruption of intracellular enzymatic pathways, and the induction of apoptosis or immune-mediated cell lysis (Source: Nature Reviews Drug Discovery, 2020). For broad-spectrum agents like porfimer sodium, the drug binds to these proteins and, upon activation by light, generates reactive oxygen species that cause cellular damage (Source: FDA Label for Photofrin).